A large body of data from epidemiologic, clinical trial, animal, and in vitro studies demonstrate adverse consequences of industrially synthesized trans fatty acids (TFAs) on the risk of coronary heart disease (CHD). A growing database of more recent research from virtually all experimental models demonstrates evidence of detrimental consequences of TFAs on the risk of diabetes. Evidence is accumulating about the physiological and cellular mechanisms of action that account for the many adverse effects TFAs have on CHD and diabetes. In a relatively short period of time (i.e., from around the early 1990s to the present time, or almost 20 years), we have gained a good understanding of the health effects of TFAs from epidemiologic studies, clinical trials/studies, animal research, and in vitro experiments that collectively justify current dietary recommendations made by numerous government agencies and health organizations to consume a diet with as little TFAs as possible. Public policy actions have been implemented and TFAs appear on the Nutrition Facts Panel. Some cities have also mandated zero TFAs in restaurants. The research on TFAs is a good example of how an evidence base has been built and translated into public policy that targets improved health. It is impressive that the TFA research has been coupled to public policy actions to decrease TFAs in the food supply so quickly.
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Over the next decade, additional epidemiologic studies were published that showed a consistent adverse association of TFAs with increased CHD risk (reviewed by Mozaffarian et al., 2006) . In addition, well-controlled, clinical studies were conducted that showed a dose-response relationship between dietary TFAs and LDL-C (Judd et al., 2002; Lichtenstein et al., 1999) . Collectively, the clinical studies demonstrated a dose-response relationship between TFA intake and TC/HDL-C (reviewed by Ascherio et al., 1999) . Meta-analyses evaluated the effects of substituting TFAs for carbohydrate calories and demonstrated an LDL-C raising effect that was similar to SFAs; however, unlike SFAs, TFAs did not raise HDL-C (Mensink et al., 2003) , resulting in the conclusion that TFAs lower HDL-C compared to SFAs and consequently increase the LDL-C/HDL-C ratio, which is a strong independent risk factor for CVD.
In a relatively short period of time, there has been an impressive evolvement of the evidence base demonstrating an adverse relationship between TFA intake and CHD risk. The epidemiologic studies were instrumental in establishing the rationale for conducting well-controlled clinical studies that definitively demonstrated the role that TFA intake played in CHD risk. The proliferation of the evidence base was key for the current actions/policies that have been implemented to decrease TFAs in the food supply. The emerging data or TFA intake and diabetes incidence (Riserus et al., 2009 ) insulin resistance and adiposity (Teegala et al., 2009 ) could reinforce the importance of decreasing TFAs in the diet. It will be interesting to see how this story will unfold. Other emerging questions about TFAs to resolve include determining the effects of animal TFAs versus industrially synthesized TFAs (Willett and Mozaffarian, 2008) and the biological effects of the individual industrially synthesized TFA (Lemaitre et al., 2006) . Nonetheless, it is beyond debate that removing industrially produced TFAs from the diet will decrease risk of chronic disease(s) such as CHD and, possibly, diabetes.
